Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response

S. R. Marder, K. K. Midha, T. Van Putten, M. Aravagiri, E. M. Hawes, J. W. Hubbard, G. McKay, J. Mintz

Research output: Contribution to journalArticlepeer-review

32 Scopus citations

Abstract

The levels of fluphenazine and fluphenazine sulphoxide in schizophrenic patients who were randomly assigned to receive either 5 mg or 25 mg of fluphenazine decanoate every two weeks were monitored. Patients treated with 25 mg of fluphenazine decanoate required three months to reach a steady-state plasma level, indicating that those patients who are being converted from oral to depot fluphenazine should continue to receive oral supplementation during the first three months of treatment with fluphenazine decanoate. Plasma levels of fluphenazine sulphoxide were lower than levels of fluphenazine. At six and nine months following randomisation, there was a statistically significant relationship between lower fluphenazine plasma levels and an increased risk of psychotic exacerbations. A relatively weak relationship was found between fluphenazine plasma levels and akinesia, but non-significant relationships between fluphenazine levels and other neurological side-effects including akathisia, retardation, and tardive dyskinesia. Monitoring the plasma levels may be helpful to clinicians who are attempting to treat stabilised patients with the lowest effective dose of fluphenazine decanoate.

Original languageEnglish (US)
Pages (from-to)658-665
Number of pages8
JournalBritish Journal of Psychiatry
Volume158
Issue numberMAY
StatePublished - Jan 1 1991
Externally publishedYes

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response'. Together they form a unique fingerprint.

Cite this